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Alpha-1 antitrypsin deficiency is linked with an increased risk of suffering from lung emphysema. This
discovery from the 1960s led to the development of the protease–antiprotease (im)balance hypothesis:
Overshooting protease concentrations, especially high levels of elastase were deemed to have an destruc-
tive effect on lung tissue. Consequently, it was postulated that efficient elastase inhibitors could alleviate
the situation in patients. However, despite intensive drug discovery efforts, even five decades later, no
neutrophil elastase inhibitors are available for a disease-modifying treatment of (cardio)pulmonary dis-
eases such as chronic obstructive pulmonary disease. Here, we critically review the attempts to develop
effective human neutrophil elastase inhibitors while strongly focussing on recent developments. On
purpose and with perspective distortion we focus on recent developments. One aim of this review is
to classify the known HNE inhibitors into several generations, according to their binding modes. In
general, there seem to be three major challenges in the development of suitable elastase inhibitors: (1)
assuring sufficient potency, (2) securing selectivity, and (3) achieving metabolic stability especially under
pathophysiological conditions. Impressive achievements have been made since 2001 with the identifica-
tion of potent nonreactive, reversible small molecule inhibitors. The most modern inhibitors bind HNE via
an induced fit with a frozen bioactive conformation that leads to a significant boost in potency, selectiv-
ity, and stability (‘pre-adaptive pharmacophores’). These 5th generation inhibitors might succeed in
re-establishing the protease–antiprotease balance in patients for the first time.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Human neutrophil elastase (HNE, EC 3.4.21.37) is a proteolytic proteins (e.g., the outer cell wall proteins of Gram-negative bacte-
enzyme belonging to the chymotrypsin-like family of serine
proteases. This highly active protease has revealed a broad
substrate specificity and is one of the few proteases which are able
to degrade the extracellular matrix protein elastin, giving rise to
the enzyme’s name. In particular, HNE is capable of breaking down
mechanically important structures of (1) the body’s own cellular
matrix (e.g., proteins like collagen and fibronectin) and (2) foreignria). Furthermore, the enzyme cleaves a variety of endogenous and
exogenous proteins thereby modulating their biological activity,
including (1) activation of other bioactive proteases, (2) liberation
of growth factors and the shedding of cell-surface-bound receptors,
and (3) inactivation of endogenous proteinase inhibitors and
exogenous virulence factors. In summary, HNE plays a pivotal role
in the innate immune response (host defense against bacteria), in
tissue remodeling processes, and in the onset and resolution of
inflammation.1
The activity of this Janus-faced protease is strictly regulated to
avoid uncontrolled proteolysis and inflammation in the body by
(1) channeling the potentially devastating protease to specialized
compartments (e.g., storage in azurophil granula in the cytoplasm
of neutrophils), and (2) the presence of extracellular neutraliz-
ing, endogenous serine protease inhibitors (SERPINs), for example,
alpha-1 antitrypsin (AAT, also known as alpha-1 proteinase
inhibitor, a-1 PI), which constitute and maintain the protease–
antiprotease balance.2,3
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prohibiting any proteolytic activity. However, elastase is activated
via mild alkalosis during the fusion of the granula with vacuoles
that carry bacteria. This step generates so called phagolysosomes,
the site where engulfed bacteria are destroyed (Fig. 1, step 1;
Table 1).4,5 Upon neutrophil activation, the intracellular granula
fuse with the cell membrane which dramatically enlarges the
neutrophil cell surface area (lamellipodia phenotype) and triggers
a neutrophil oxidative burst (Fig. 1, step 2). Active enzyme is then
liberated into the extracellular space with approximately 10% of
the secreted elastase bound to the neutrophil cell membrane. From
this point on ‘free’ elastase can potentially be neutralized by
binding of antiproteases that are abundantly found in plasma.
However, at the site of liberation, the millimolar concentration of
elastase still outcompetes the micromolar concentration of extra-
cellular antiprotease. More distant from the site of degranulation,
the elastase concentration decreases due to diffusion/dilution until
‘free’ elastase is completely neutralized. Consequently, only a smallFigure 1. Schematic representation of the human neutrophil elastase (HNE) life
cycle: Elastase is activated during the depletion of the acidic storage granula
(circles) and (1) liberated into the cytoplasmic phagolysosomes (oval) with
engulfed bacteria (green rectangle) or (2) into the extracellular space. Free
extracellular elastase is neutralized via binding to antiproteases. The efficiency of
neutralization depends on the spatiotemporal stoichiometry of both binding
partners, details see Figure 16. Besides HNE, the storage granula bear two further
proteases (cathepsin G, proteinase 3) and the enzyme myeloperoxidase (MPO)
involved in the neutrophil oxidative burst (yellow star).
Table 1
Relationship of the neutrophil state to elastase localization and biological function
(NET = neutrophil extracellular trap)
Neutrophil
state
Elastase localization Biological function
Resting Intracellular (granula) Storage
Activated Intracellular (phagolysosome) Host defense
Activated Extracellular (free and
membrane-bound)
Inflammatory response, tissue
remodeling
Dying Extracellular (NET-bound) Resolution of inflammation,
host defensespace of obligate elastase activity exists around activated
neutrophils in a healthy situation.6–8
On the other hand, elastase is also involved in the resolution
of the inflammation (Table 1). Activated, pro-inflammatory
neutrophils enter an elastase-dependent programmed cell death
process (NETosis) where elastase is translocated to the cell nucleus
and undergoes condensation with DNA and histone proteins.
Then the dying neutrophils disintegrate and produce neutrophil
extracellular traps (NETs) comprised of long extracellular ‘fila-
ments’ of DNA with bound proteins, such as histones, elastase,
and myeloperoxidase (MPO). These filaments are also able
to trap bacteria and fungi, and hamper a fast spread of these
microorganisms.9,10
Out-of-balance elastase activity contributes to the onset and
progression of many inflammatory diseases with severe impact
on organ tissue integrity. Chronic obstructive pulmonary disease
(COPD) is regarded as the traditional target indication for any elas-
tase inhibitor treatment therapy since a cohort of humans lacking
sufficient amounts of the antiprotease AAT demonstrated a signif-
icantly higher risk of suffering from lung emphysema as a common
form of COPD (AAT-deficiency, AATD as defined above).11 In addi-
tion to the common disease COPD, some other more rare inflam-
matory conditions or orphan diseases are also characterized by a
disturbed protease–antiprotease balance (Fig. 2). There is also good
evidence for this out-of-balance elastase activity from experimen-
tal pharmacological data with protease knockout or transgenic
antiprotease rodents in pulmonary disease models.12–18 In this
review, we focus on (cardio)pulmonary diseases only, such as
COPD, cystic fibrosis (CF), bronchiectasis (BE), pulmonary arterial
hypertension (PAH), pulmonary fibrosis, and acute lung injury
(ALI). Other important neutrophil-driven inflammatory diseases,
such as rheumatoid arthritis and inflammatory bowel disease, will
not be discussed.
Evolution of relevant (clinical) HNE inhibitors: There is a high
medical need for neutrophil elastase inhibitors due to the key role
of neutrophil elastase in inflammation as well as (lung) tissue
degradation and remodeling. In the last three decades many stake-
holders in academia and the pharmaceutical industry have discov-
ered a variety of innovative elastase inhibitors. We will briefly
summarize this evolution of HNE inhibitors along five generations.
Beginning with biologicals (1st generation), ultimately a novel
pre-adaptive pharmacophore model has given rise to presumably
the best-in-class elastase inhibitors to date (5th generation). Many
of these compounds have picomolar potency, are highly selective
and show drug-like pharmacokinetics.
Although neutrophil elastase inhibitors from natural products
have been described frequently (e.g., flavonoids, cinnamic and
caffeic acid derivates, and cyclic peptolides), many of these small
to mid-size molecules have revealed only a weak or moderate
potency, limited selectivity, and serious metabolic liabilities whichProtease
Anprotease
COPD, CF, BE,
ALI, ARDS, SIRS,
PH, PAH, NSCLC
AATD
Figure 2. Protease–antiprotease imbalance in pulmonary diseases: Elastase poten-
tially plays a key role in many pulmonary diseases where the protease–antiprotease
balance is disturbed.
Figure 3. Selection of 1st generation neutrophil elastase inhibitors (biologicals): (A) a-1 PI (Prolastin, Zemaira, Aralast; Ki < 0.1 nM) and (B) elafin (tiprelestat, Ki 0.08 nM)
displayed as the protease–antiprotease complexes. The different size of both antiproteases is notable. Both figures were generated by superimposing an in-house neutrophil
elastase crystal structure with PDB entries 2D26 and 1FLE, respectively, using the program Discovery Studio. (A) Porcine pancreatic elastase (dark blue)/a-1 PI (bordeaux red);
(B) porcine pancreatic elastase (dark blue)/elafin (bordeaux red).
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such early-stage inhibitors have been reviewed elsewhere,19 they
will not be further considered here.
1st generation (biologicals): Following the principal idea of
highly specific, complementary binding partners, as proposed in
H.E. Fischer’s Lock and Key Model, the 1st generation of neutrophil
elastase inhibitors commenced with the natural counterparts of
elastase. For example, the endogenous antiprotease a-1 PI
(Prolastin, Zemaira, Aralast) compromises a highly complemen-
tary tertiary structure to elastase and has been used as an augmen-
tation therapy for AATD patients (Fig. 3). Originally isolated from
human plasma, modern variants are derived from recombinant
sources to better accommodate potential safety and cost
issues.20,21 The most important antiproteases are a-1 PI (AAT),
elafin, and secretory leukocyte protease inhibitor (SLPI) which
are capable of inhibiting the most prominent neutrophil serine
proteases stored in the cytoplasmic azurophil granula: HNE,
proteinase 3 (PR3), and cathepsin G (CatG).
The antiproteases interact along the enzyme’s substrate binding
cleft covering manifold contacts with the target at the substrate
pockets S5–S30 (nomenclature according to Schechter and Berger)
which translates into a very tight, pseudo-irreversible binding
(Fig. 4).
A major drawback of these 1st generation inhibitors is a lack of
stability especially under pathophysiological, oxidative stress con-
ditions: (1) host and/or microbial proteases can partially degrade
the antiproteases and thereby impede the inhibitory function,22,23
and (2) oxidation of vulnerable methionine residues results in a
significantly lower inhibitory capacity.24–27 In addition, a-1 PI is
unable to efficiently inhibit membrane-bound neutrophil elas-
tase.28 This is most probably due to a steric hindrance of this large
antiprotease and the unique conformational change upon bindingFigure 4. Crystal structure of HNE in complex with 1st generation inhibitor SLPI (green;
Connolly-like surface (grey). (A) View from above into the substrate binding cleft of HNE
HNE is displayed in helix/ribbon and backbone representation (green) with side-chain r
subsites S5–S4–S3–S2–S1–S10–S20–S30 and the bound SLPI inhibitory loop residues in st
perfectly fills the substrate binding cleft characterized by the deep S1 pocket.its protease counterpart, translocating the antiprotease on the
opposed side of the protease.29
Furthermore, the intrinsic physicochemical properties of these
biologicals allow only for an intravenous or a potentially inhalative
administration route, and thus hamper a broad and repetitive oral
usage in chronic diseases like COPD. Consequently, their current
clinical development is focused on more acute settings with intra-
venous or inhaled applications, such as clinical Phase II tests with
(1) elafin (tiprelestat) for the prevention and treatment of
postoperative inflammatory complications in esophagus carci-
noma surgery, coronary artery bypass surgery, and kidney trans-
plantation,30 or (2) AAT for the prevention of bronchiolitis
obliterans syndrome (BOS) in lung transplant recipients,31 acute
graft-versus-host disease,32,33 acute inflammatory response in
acute myocardial infarction,34 and post-cardiac surgery systemic
inflammatory response.35
2nd generation (mechanism-based suicide SMOLs): Along the lines
of Paul Ehrlich’s Pharmacophore Model, a more detailed analysis of
the substrate recognition and enzymatic reaction mechanism of
serine proteases led to the first small molecule (SMOL) inhibitors
with active-site recognition. In order to ensure sufficient potency
these inhibitors were typically based on a covalent reversible or
irreversible binding mechanism.
In contrast to the 1st generation elastase inhibitors, these low-
molecular weight molecules are, in principle, able to reach and
inhibit also membrane-bound elastase (see Fig. 1). Of further
importance, such inhibitors might be able to enter neutrophil cells
and thereby interfere with the host defense function of elastase.
First examples have been various peptide-based SMOL inhibitors
or peptidomimetics, followed by non-peptide-based inhibitors
(Fig. 5). In general, all these 2nd generation inhibitors have
displayed a mechanism-based, reactive mode of action (suicidePDB entry 2Z7F): The protease is shown in a stick representation with transparent
(grey); the domain of the antiprotease involved in protein–protein interactions with
esidues in sticks; (B) detailed view of the HNE substrate binding cleft with labeled
icks (carbon, green; oxygen, red; nitrogen, blue; sulfur, yellow). The inhibitory loop
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Michael acceptors, or electrophilic ketones (transition-state mim-
ics). Almost every large pharmaceutical company has had an elas-
tase inhibitor program, resulting in a myriad of HNE inhibitors
with many different reactive pharmacophores.19,36–41
These mechanism-based elastase inhibitors interact in a cova-
lent manner with the enzyme’s active site, namely by electrophilic
attack of Ser195 (chymotrypsin numbering, Fig. 6). A proper posi-
tioning of the reactive moiety of the inhibitor is achieved through
guiding interactions of the P4–P1, P20, and P30 residues of the
inhibitor (Fig. 7). Thus, similar to the 1st generation elastase
inhibitors, the interaction with the target basically occurs along
the substrate binding cleft (Fig. 8).42 In general, interaction with
the P1 moiety of a substrate or inhibitor is reflected as the most
assertive interaction with regard to target specificity, matching
the pronounced S1 binding pocket.43,44
However, due to the inherent reactive nature of these inhibi-
tors, the compounds in general suffer from not optimal pharma-
cokinetic properties (metabolic liabilities) and/or adverse events
(due to lack of specificity). Not surprisingly, few compounds have
revealed acceptable drug-like properties allowing for a safety and
efficacy assessment in humans. Overall, the clinical outcome has
been disappointing with only sivelestat (7, Elaspol) reaching the
market for the treatment of ALI/ARDS in Japan and South Korea
in 2002 and 2006. To date, efforts to enlarge the country or indica-
tion scope of Elaspol have failed.
Sivelestat (7) has only a moderate potency (Ki 200 nm) and
selectivity versus off-targets such as porcine pancreatic elastase
(IC50 5.6 lm).45 The drug has to be administered strictlyintravenously, as the pharmacokinetic profile does not allow for
an oral administration.46,47 The clinical efficacy of sivelestat (7)
remains controversial. Local Japanese studies and multinational
studies on the treatment of patients with ALI associated with SIRS
have revealed seemingly inconsistent results with regard to
improvements in ventilator-free days, ICU-free days, and long-
term survival.48–52
3rd and 4th generation (modern, non-mechanism-based SMOLs):
The 3rd and 4th generation of neutrophil elastase inhibitors are
characterized by nonreactive, reversible inhibitors originating from
pyridone and dihydropyrimidinone lead structures independently
published by AstraZeneca in 2002 and Bayer in 2001 (Figs. 9 and
10). A unique binding mode in the active center of the enzyme
(S1 pocket) triggers a conformational change in the protease
creating a de novo formed deep S2 pocket enabling further
unprecedented target interactions.53 This remarkable binding
feature could be described as being analogous to the Induced Fit
Model proposed by D.E. Koshland. Notably, this interaction does
not follow the linear topology of the substrate binding cleft as it
is the case with the 1st and 2nd generation inhibitors. On the
contrary, the orientation of 3rd and 4th generation inhibitors is
almost perpendicular to the natural substrate binding cleft.
Whereas 3rd generation inhibitors only occupy the S1 pocket of
the enzyme, 4th generation inhibitors also bind to the deepened
S2 pocket.
Based on their improved drug-like properties the two new lead
structure series were highly stimulating for the preclinical devel-
opment of elastase inhibitors and elicited a lot of activity both
within companies and beyond.19,54–57 To date, two optimized,
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and BAY-678 (17) have entered clinical testing.
Both clinical candidates AZD9668 (13) and BAY-678 (17) con-
tain an identical S1 binding motif [m-(trifluoromethyl)phenyl].
An X-ray structure of HNE-bound 12 (a close congener of 13) has
surprisingly revealed that this S1 binding motif in conjunction
with the central pyridone scaffold apparently widens the remote
S2 pocket significantly (Fig. 11). In the case of 18 (a close congener
of 17), the enlarged S2 pocket is perfectly filled with the p-cyano-
phenyl moiety (Fig. 12). More elaborate molecules with additional
target interactions show an even improved (subnanomolar)
potency relative to the clinical candidates: namely, congeners of
AZD9668 (13) with an additional S2 binding motif, such as 15
(p-cyanophenyl), or congeners of BAY-678 (17) with additionalpotential contacts along the S0 substrate binding cleft, such as 19
(carboxylic acid side chains).57 These modern inhibitors have dis-
played an outstanding selectivity versus similar serine proteases
and a very high target specificity with no significant interactions
with other pharmaceutically relevant targets, in contrast to 2nd
generation inhibitors such as the potent, orally bioavailable, but
reactive clinical candidate ONO-6818 (8, freselestat).59
AZD9668 (13) and BAY-678 (17) have revealed significant effi-
cacy in preclinical models of ALI and lung emphysema, demon-
strating their anti-inflammatory and anti-remodeling mode of
action. Additionally, BAY-678 (17) has shown significant beneficial
pulmonary hemodynamic and vascular effects in models of PAH in
rats and mice.61–63
The safety and efficacy of AZD9668 (13) and BAY-678 (17) have
been initially assessed in clinical Phase I trials with healthy
volunteers and with COPD patients. All these trials have confirmed
a very good safety and tolerability of these two 3rd and 4th
generation elastase inhibitors. Both compounds are suitable for a
chronic twice daily oral administration.64 Noteworthy, the clinical
development of the 2nd generation inhibitor ONO-6818 (8) has
been discontinued due to abnormal elevation of liver function test
values.65 BAY-678 (17) is nominated as a chemical probe to the
public via the Structural Genomics Consortium (SGC).66
From bench to bedside: Although HNE is an accepted target in the
scientific community, the inhibition of the enzyme remains an
innovative approach from the clinical perspective. There is still
Figure 8. Crystal structure of HNE in complex with 2nd generation trans-lactam inhibitor GW475151 (3) a close congener of GW311616A (2) (PDB entry 1H1B): The protease
is shown in a stick representation with transparent Connolly-like surface; ligand 3 (green) is shown as balls and sticks. Heteroatoms are colored as follows: oxygen, red;
nitrogen, blue; sulfur, yellow. (A) View from above into the substrate binding cleft of HNE with deep S1 pocket; (B) detailed view of the covalent binding of the reactive
N-methanesulfonyl-lactam moiety of the inhibitor (bright ball and sticks) to Ser195 (chymotrypsin numbering) of HNE (dark ball and sticks).
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show beneficial clinical effects. Furthermore, it is not clear whether
a sole inhibition of elastase will have a meaningful effect in
patients. In a base case scenario, the aim might be a 50–90% inhi-
bition range of elastase to foster (presumably) beneficial clinical
effects without potentially hampering the innate immune response
function of the target.
Besides traditional human dose estimates based on experimen-
tal pharmacology and drug metabolism and pharmacokinetics
(DMPK) data, an additional attractive tool might be elastase activ-
ity assessment in human plasma after an ex vivo zymosan chal-
lenge in whole blood. Here, the yeast cell wall component
zymosan is applied ex vivo in whole blood to activate resting neu-
trophils and thereby to elicit a sterile inflammation comprised of
the typical morphological change of the neutrophil cells and the
exhaustive depletion of the HNE-bearing granula.67 In contrast to
in vitro tests which in general apply isolated, highly purified neu-
trophil elastase, this ex vivo test makes use of neutrophil cells as
the source for in situ liberated elastase molecules. Thus, the
ex vivo conditions integrate many more features of the complex
(patho)physiological conditions present in a neutrophil-driven
inflammation in vivo than any in vitro test could incorporate,including: (1) the presence of antiproteases in whole blood reflect-
ing the endogenous protection shield (protease–antiprotease bal-
ance), (2) the presence of other plasma proteins and components
(e.g., albumin), and (3) oxidative stress conditions during neu-
trophil activation.
When this procedure was applied after oral administration of
the drug in healthy volunteers and in COPD patients, AZD9668
(13) displayed a dose-dependent ex vivo inhibition of neutrophil
elastase in whole blood around Cmax values (1–4 h). However, at
24 h, only one dose (60 mg twice daily) revealed a relevant inhibi-
tory capacity with approximately 50% inhibition. Higher doses did
not translate into a higher target inhibition at 24 h, although Cmax
and AUC (0–24 h) were dose-proportional over the entire dose
range. The reason for this is not known; it might be surmised
and speculated that AZD9668 (13) is not sufficiently stable, for
example, under sustained oxidative stress conditions.68 Based on
these data, a dose of 60 mg b.i.d. AZD9668 (13) has been orally
administered to assess safety and efficacy in CF, BE, and COPD
patients.
In these clinical Phase II studies, AZD9668 (13) was safe and
well tolerated. Besides some promising results in a small study
with BE patients or in a subgroup of a larger COPD trial, in general
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lung function parameters and quality of life). However, some
promising effects with regard to secondary outcome parameters,
such as inflammatory or mechanistic biomarkers, were seen.68–71
Most probably, the treatment duration in these studies was too
short for a disease-modifying treatment (4-week and 12-week
treatment in BE/CF and COPD patients, respectively) to expect
significant changes in the primary clinical objectives.72 Recently
published data for the cytokine receptor CXCR2 antagonist MK-
7123 in a 26-week dose-finding study in COPD patients revealed a
significant effect on neutrophil sputum count and some effects on
inflammatory biomarkers after 12 weeks; however, effects on lung
function were only demonstrated after 26 weeks.73 There were no
effects on the rate of exacerbations. Apparently, an even longer
study duration is necessary to demonstrate efficacy concerning
exacerbations, as shown with the two 1-year trials with the phos-
phodiesterase PDE4 inhibitor roflumilast in COPD patients.74,75
AZD9668 (13) is currently available within AstraZeneca’s open
innovation initiative.
BAY-678 (17) has not entered Phase II trials due to a switch to a
significantly improved follow-up HNE inhibitor, BAY 85-8501 (22)
(see 5th generation HNE inhibitors).
5th generation (pre-adaptive pharmacophores derived from 4th
generation inhibitors): The 5th generation of neutrophil elastase
inhibitors are structurally closely related to the 4th generation
inhibitors. However, in the 5th generation inhibitors (Fig. 13), an
additional substituent results in an unprecedented improvement
in potency though it does not directly interact with the target. In
fact, the additional substituent (e.g., SO2Me in 21, Fig. 14)76 raises
the rotational barrier at the crucial pyrimidinone-cyanophenyl axis
and thereby ‘freezes’ the structure in an ideal bioactive conforma-
tion, thus pre-organizing the inhibitor for the forthcoming binding
event. Remarkably, in this case the spatial change that will happen
within the target enzyme-upon the induced-fit binding process is
conformationally pre-empted by the inhibitor (pre-adaptive
pharmacophore model).77
For example, BAY 85-8501 (22) displays an extraordinary
potency (Ki 0.08 nm), already comparable to the endogenous
antiproteases and remarkable two orders of magnitude higher
when compared with corresponding 4th generation inhibitors
(Table 2). Furthermore, the in vitro inhibitory capacity of
BAY 85-8501 is maintained in the presence of 1 mmH2O2 (mimick-
ing oxidative stress conditions, data for other inhibitors not
published). This leap in potency comes with increased selectivity
towards other serine proteases: Most serine proteases show lesse data, PDB entry 5abw),60 a close congener of AZD9668 (13): The protease is shown
n) is shown as balls and sticks. Heteroatoms are colored as follows: oxygen, red;
te binding cleft of HNE; compound 12 binds into the S1 pocket, the formation of the
e inhibitor, the p-methylsulfonyl moiety binds into the S4 pocket; (B) detailed side
e S1 pocket and pointing towards the de novo deep S2 pocket. (See Fig. 15A for the
Figure 12. Crystal structure of HNE in complex with 4th generation inhibitor 18, a close congener of BAY-678 (17) (PDB entry 5a09): The protease is shown in a stick
representation with transparent Connolly-like surface (grey); ligand 18 (green) is shown as balls and sticks. Heteroatoms are colored as follows: oxygen, red; nitrogen, blue;
fluorine, light green. (A) View from above into the substrate binding cleft of HNE with deep S1 pocket and de novo formed S2 pocket, the inhibitor binds in an almost
perpendicular orientation; (B) detailed side view of the noncovalent, induced-fit binding of compound 18 perfectly filling the S1 pocket and the de novo formed, deep S2
pocket.
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Figure 13. Selection of 5th generation neutrophil elastase inhibitors (SMOL with
pre-adaptive pharmacophore); BAY 85-8501 (22) is currently in a Phase II trial (BE).
Again, annulated variants of the pyrimidinone core, such as triazolopyrimidines
(e.g., 26), have been prepared.78
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the typical overall fold of serine proteases with very similar active-
site geometries. Here, an unprecedented selectivity of more than
five orders of magnitude is reached with 22 (Table 3). A selectivity
of almost two orders of magnitude has even been demonstrated for
a few proteases sharing a high primary sequence identity with
HNE, for example, orthologous neutrophil elastase from rats or
mice, and proteinase 3 (PR3) with approximately 70% primary
sequence identity (no proteinase 3 inhibition data published for
BAY 85-8501).
Compared to the overall promising rodent DMPK profile of the
3rd and 4th generation inhibitors, BAY 85-8501 (22) shows a
further improved metabolic stability translating into a low clear-
ance and improved half-life with no inhibitory capacity towards
CYP isoforms.76 Studies with BAY 85-8501 (22) have confirmed
an anti-inflammatory and anti-remodeling mode of action in
preclinical acute and chronic animal models of ALI, PAH, and PH
associated with lung emphysema.76,80–82
Recently, more research groups from industry have been
attracted to 5th generation inhibitors, leading to further improve-
ments in potency and metabolic stability (23–25, Table 4;
Fig. 15).83,84
Compromising the host defense of patients has been discussed
as a hypothetical side effect of elastase inhibition. However, the
intrinsic risk of the 3rd, 4th, and 5th generation HNE inhibitors
to interfere with the host defense should be regarded as being
low because the intracellular elastase concentration is very high
(millimolar concentration range) and a potential accumulation of
HNE-bound inhibitors upon chronic treatment is unlikely due to
their nonreactive and reversible mode of action.
Clinical Phase I studies have been conducted with healthy male
volunteers to evaluate safety, tolerability, and pharmacokinetics of
once daily, orally administered BAY 85-8501 (22). In all studies, the
drug was safe and well tolerated at single and multiple doses
(tested up to 1 mg) without evidence of adverse effects related to
the drug or its mechanism of action. Exposure to BAY 85-8501
(22) increased proportionally with dose, approaching steady state
at 14 days with a half-life of 120–140 h. Renal elimination of
unchanged drug is only a minor pathway for elimination. Thus,
special precautions for the potential treatment of renal-impaired
patients are not expected. Inhibition of neutrophil elastase activity
in plasma after ex vivo zymosan challenge in whole blood was
reversible, occurred in a dose-dependent manner over the entire
dosing interval, and correlated well with the drug exposure. At
steady state, IC50 was covered with a dose >0.6 mg, while IC90
was covered with the 1-mg dose.85–87
Figure 15. Overview of the active site of HNE structure (PDB entry 5a0c) with superimp
(A–D): 15,57 22,76 20,84 and 25.79 As a common feature all these 4th and 5th generation in
S2 pocket with its para-cyanophenyl residue via a pyrazole ‘joint’ (A). In contrast, w
para-cyanophenyl residues that are directly attached to the central scaffold (B and C).
Figure 14. Crystal structure of HNE in complex with 5th generation inhibitor 21, a close congener of BAY 85-8501 (22) (PDB entry 5a0c): The protease is shown in a stick
representation with transparent Connolly-like surface (grey); ligand 21 (green) is shown as balls and sticks. Heteroatoms are colored as follows: oxygen, red; nitrogen, blue;
fluorine, light green; sulfur, yellow. (A) View from above into the substrate binding cleft of HNE with deep S1 pocket and de novo formed S2 pocket, C20–SO2Me points towards
the solvent without any target interaction; (B) detailed side view of 21 perfectly matching the induced-fit target binding geometry. [See Fig. 15B for the presumed binding
geometry of BAY 85-8501 (22).]
Table 3
Selectivity of selected examples of HNE inhibitors (reported as ratio of IC50 or Ki against the protease of interest versus the value against HNE; ⁄based on on-rates)
Protease 1st generation 2nd generation 3rd generation 4th generation 5th generation
a-1 PI78 Elafin78 ONO-5046 (7)59 ONO-6818 (8)59 AZD9668 (13)59 BAY-678 (17)76 BAY 85-8501 (22)76
HNE 1⁄ 1⁄ 1 1 1 1 1
PR3 8⁄ 1⁄ 3 63 >1900 600 —
CatG 160⁄ — >2000 >2000 >680 >660 >375000
Chymotrypsin — — 199 1000 >2000 >660 >375000
Pancreatic elastase — — 79 79 >2000 >660 >375000
Trypsin — — >2000 >2000 >2000 >660 >375000
Rat NE — — 1.1 — 18 40 100
Murine NE — — 0.4 — 24 47 75
Table 2
Potency of selected examples of HNE inhibitors
1st generation 2nd generation 3rd generation 4th generation 5th generation
a-1 PI77 Elafin77 ONO-5046 (7)45 ONO-6818 (8)42 AZD9668 (13)59 BAY-678 (17)76 BAY 85-8501 (22)76
Ki (nm) <0.1 0.08 200 12 12 15 0.08
Table 4
Comparison of potency, half-life, and clearance of the 4th generation inhibitor 20 and
derived 5th generation inhibitor derivatives 23–2584
HNE
inhibitor
HNE plasma
assay IC50 (nm)
Human
hepatocytes
half-life (min)
Predicted human
hepatic in vivo
blood clearance
CL (mL/min/kg)
20 22 >130 6
23, 24, 25 <1 >130 0
4378 F. von Nussbaum, V. M.-J. Li / Bioorg. Med. Chem. Lett. 25 (2015) 4370–4381Consequently, a dose of 1 mg (orally once daily treatment) was
selected to initially assess the safety of BAY 85-8501 (22) in
patients and to evaluate efficacy. Here, a 4-week clinical Phase II
study with 92 NCF BE patients (NCT No. 01818544, study com-
pleted with no results published so far) was conducted with a
design resembling the exploratory trial with AZD9668 (13) (vide
supra).
Further neutrophil elastase inhibition principles: Peptidic inhibitors
and gene therapy: The design of peptidic inhibitors combines theosed ligands in order to display the prooven and/or presumed binding geometries.
hibitors clamp the S1 and S2 pocket. Notably, the pyridone 15manages to reach the
ithin the entire pyrimidinone series, diving into the S2 pocket is possible with
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Figure 16. Schematic representation of the protease–antiprotease (im)balance and the subsequent partition of free and captured HNE; in (III), binding to alpha-2
macroglobulin (A2M) and polyanionic surfaces, for example, DNA filaments in NETosis (helix symbol) and heparan sulfates (carbohydrate symbol); the size of the circles/
squares reflects the relative amounts of free/captured elastase (not proportional). A SMOL inhibitor could potentially shift the system from sustained inflammation (III) to a
more healthy stage (I).
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create ‘hybrid’ 1st/2nd generation inhibitors. However, peptides
often suffer from a poor pharmacokinetic profile and none of the
linear or cyclic elastase inhibitory peptides derived from phage dis-
play campaigns has turned out to be a drug-like molecule allowing
clinical testing. The situation seems to be better for the b-hairpin
peptide POL6014 that might enter clinical testing in the future
following a strict inhaled administration protocol. Start of clinical
phase 1 testing is planned in 2015.88 This peptide has been discov-
ered with a so-called protein epitope mimetic (PEM) technology
starting from a natural b-hairpin-bearing, reactive-site loop of
the Bowman–Birk family of serine proteases.89,90 Derivatization
of this loop motif occurred via the exchange of building blocks in
a solid-phase synthesis which enabled the generation of a peptide
library in a combinatorial-chemistry-like manner, including
non-proteinogenic amino acids or unrelated building blocks. The
structure of POL6014 is yet to be disclosed including further infor-
mation on whether POL6014 still bears the disulfide bridge of the
natural template. Nebulized POL6014 revealed preclinical efficacy
in ALI models and concentration in the lungs was 100-fold higher
than in plasma.91–93
A variation of the augmentation therapy (1st generation
inhibitors) has been used to treat patients with the DNA ‘blueprint’
of the antiprotease rather than with the protein itself. In general,
these gene therapy treatment efforts face the issue of a sufficient
and controlled delivery of the DNA-bearing vector to the tissue
of interest. First clinical attempts are underway.94–96 Another
variation to interfere with the protease–antiprotease imbalance
applies RNA interference strategies (e.g., shRNA and miRNA) which
have only been explored preclinically so far.95
Outlook: Challenges and opportunities: Disease-modifying thera-
pies for the aforementioned pulmonary diseases are innovative
from the clinical perspective as the medical need for such treat-
ments is very high. One big challenge is that a disease-modifying
therapy with an anti-inflammatory and anti-remodeling treatment
will potentially not have an immediate impact on relevant clinical
parameters (e.g., lung function and quality-of-life scores) com-
pared to a symptomatic therapy (e.g., bronchodilator treatment).
Consequently, clinical trials with significantly longer treatment
durations will probably have to be conducted to achieve a proof-
of-concept. In particular, this is the case for exacerbation rates.97Furthermore, a direct demonstration of an anti-remodeling treat-
ment effect likely demands a patient cohort with a minor disease
severity to better monitor the progression of the disease (longitu-
dinal evaluation of high-resolution computed tomography scans,
HRCT), presumably resulting in even longer clinical trials. Such
trials are typically risky and expensive.
A neutrophil elastase inhibitor treatment in a clinical setting
needs to take into account the protease–antiprotease imbalance
in the respective disease. In general, an area of obligate HNE activ-
ity exists around activated neutrophils where the local concentra-
tion of the liberated elastase is higher than the apparent
concentration of the antiproteases (see introduction and Fig. 1).
This general scenario is reflected in the ex vivo testing of
neutrophil elastase activity after zymosan challenge in whole
blood samples (see 3rd, 4th, and 5th generation inhibitors).
However, the spatiotemporal dimensions of this area might be
larger at the pathophysiological sites in diseased tissue (with sus-
tained inflammation) where the partition of the active protease
and effective antiprotease might be different to the situation in a
de novo inflammation (in situ elicited inflammation). In certain
pathophysiological conditions, active elastase is captured in com-
peting ‘micro-compartments’ circumventing an efficient neutral-
ization by antiproteases (Fig. 16). For example, similar to the
situation of elastase embedded in the neutrophil membrane, the
active protease is partially protected from the antiprotease upon
binding to alpha-2 macroglobulin or polyanionic binding partners
such as (1) heparan sulfate components of syndecan-1 in the spu-
tum of BE patients,98,99 and (2) nucleic acid filaments in neutrophil
extracellular traps of dying neutrophils (NETosis) in sputum and
blood samples of patients with BE, CF, tuberculosis, and sep-
sis.100,101 Thus, not only neutrophil elastase derived from freshly
activated neutrophils, but also that derived from the ‘debris’ of pre-
viously engaged neutrophil cells, will contribute to the overall
elastase activity which is not adequately addressed by the antipro-
teases.102 Furthermore, the inhibitory capacity of the antiproteases
is hampered in certain pathophysiological conditions. For example,
bacteria are not effectively cleared from the airways of CF or BE
patients and bacterial proteases could degrade the antiproteases.
Environmental (tobacco smoke, air pollution) or genetic (AATD)
factors could further decrease the effective antiprotease concentra-
tion in patients.103 The partition is further influenced by a different
4380 F. von Nussbaum, V. M.-J. Li / Bioorg. Med. Chem. Lett. 25 (2015) 4370–4381vulnerability of the three major antiproteases (a-1 PI, SLPI, elafin)
towards oxidation and affinity towards the three major neutrophil
serine proteases (HNE, CatG, PR3).79,104,105 To date, it is still uncer-
tain how high the spatiotemporal concentration of active elastase
(and other proteases) really is in such disease settings!
Thus, aiming for a 50–90% inhibition of elastase, the necessary
dose for a clinical elastase inhibitor treatment might be higher
than the estimated dose based on ex vivo whole blood testing or
preclinical models which, in general, do not reflect any mucus-
ridden airways/lungs. Noteworthy, the dose of AZD9668 (13,
60 mg b.i.d.) in clinical testing was close to the 70 mg b.i.d. limit
based on preclinical toxicological data, which does not allow for
a significant further dose escalation.64,71
Nevertheless, neutrophil elastase inhibitors of the 5th genera-
tion bear the potential to overcome at least some of these
challenges in order to re-establish the protease–antiprotease
balance in patients. Their higher potency and selectivity should
allow for higher daily doses due to a presumably better safety
profile. Hopefully this will stimulate multiple players in the field
to enter extended proof-of-concept clinical trials in disease
modifying treatment regimens. These treatments might be applied
in conjunction with other therapies such as DNAse, mucolytics,
antibiotics, and tobacco dehabituation. In addition, easy access to
chemical tools such as AZ9668 (13) and BAY-678 (17) should
further support many labs investigating the important biology of
HNE in multiple disease settings.
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